Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | Cellular therapy: a key part of EBMT 2017

Nicolaus Kröger • 26 Mar 2017
EBMT 2017
Acute Myeloid Leukemia Multiple Myeloma Myelofibrosis Myeloproliferative Neoplasms

Nicolaus Kröger, MD, from the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, speaks about how the rising field of cellular therapy has been one of the essential parts of the 2017 EBMT meeting. He highlights debates about how to avoid relapse after stem cell transplantation in hematological malignancies, as well as the rising field of cell therapy. Recorded at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Marseille, France.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
0:51
The need for disease-modifying drugs in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals